AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30475957 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent Calorie Restriction (ICR) - 5:2 diet (5 days without energy restriction and 2 days with 75% energy deficit)
Number of subjects: 150
Study 30475957 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Calorie Restriction (CCR) - daily energy deficit ∼20%
Number of subjects: 150
Study 30475957 — intervention group
Group type: COMPARATOR
Intervention: Control group - no advice to restrict energy
Number of subjects: 150
Study 30475957 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent Calorie Restriction (ICR)
Number of subjects: 150
Study 30475957 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Calorie Restriction (CCR)
Number of subjects: 150
Study 30475957 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 150
Study 28749419 — intervention group
Group type: EXPERIMENTAL
Intervention: 28 g of whole, lightly salted roasted almonds
Number of subjects: 22
Study 28749419 — intervention group
Group type: COMPARATOR
Intervention: Isoenergetic baked food
Number of subjects: 22
Study 26785372 — intervention group
Group type: EXPERIMENTAL
Intervention: BCAA + OA supplementation (16 g BCAA and 12 g OA)
Number of subjects: 11
Study 26785372 — intervention group
Group type: COMPARATOR
Intervention: Flavoured water (placebo)
Number of subjects: 11
Study 21783387 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride
Number of subjects: 60
Study 21783387 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose Flutamide
Number of subjects: 60
Study 21783387 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 21226758 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual therapy and child physiotherapy
Number of subjects: 32
Study 21226758 — intervention group
Group type: COMPARATOR
Intervention: Child physiotherapy alone
Number of subjects: 32
Study 18192850 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol (5 mg)
Number of subjects: 16
Study 18192850 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (50 mg)
Number of subjects: 16
Study 18192850 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 16
Study 16644641 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 31
Study 16644641 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 12851191 — intervention group
Group type: EXPERIMENTAL
Intervention: Safehip hip protectors
Number of subjects: 366
Study 12851191 — intervention group
Group type: COMPARATOR
Intervention: Control group (no hip protectors)
Number of subjects: 366
Study 10823258 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly self-testing and self-dosing
Number of subjects: 102
Study 10823258 — intervention group
Group type: COMPARATOR
Intervention: Standard management
Number of subjects: 102
Study 8877665 — intervention group
Group type: EXPERIMENTAL
Intervention: Triclosan-containing mouthrinses
Number of subjects: 30
Study 8877665 — intervention group
Group type: COMPARATOR
Intervention: Control rinse
Number of subjects: 30
Study 1739562 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 0.1 mg kg‐1
Number of subjects: 10
Study 1739562 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 6337988 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefaclor 500 mg three times daily
Number of subjects: 80
Study 6337988 — intervention group
Group type: COMPARATOR
Intervention: Amoxycillin 500 mg three times daily
Number of subjects: 80
Study 6337988 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefaclor and Amoxycillin
Number of subjects: 80
Study 31187506 — intervention group
Group type: EXPERIMENTAL
Intervention: Romantic rejection by desired dating partners (for males)
Number of subjects: 0
Study 31187506 — intervention group
Group type: COMPARATOR
Intervention: Romantic rejection by desired dating partners (for females)
Number of subjects: 0
Study 31187506 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased feelings of anger (for males)
Number of subjects: 0
Study 28612671 — intervention group
Group type: EXPERIMENTAL
Intervention: MgSO4
Number of subjects: 1894
Study 28612671 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1894
Study 27596244 — intervention group
Group type: EXPERIMENTAL
Intervention: m-Health technology-enabled, nurse-led intervention including a pillbox, Blue-toothed UA-767Plus BT BP device, and smartphone for monitoring BP and medication intake under nurse guidance for 3 months.
Number of subjects: 60
Study 27596244 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (control group).
Number of subjects: 60
Study 27596244 — intervention group
Group type: EXPERIMENTAL
Intervention: m-Health technology-enabled, nurse-led intervention.
Number of subjects: 60
Study 24526821 — intervention group
Group type: EXPERIMENTAL
Intervention: ω-3 PUFAs supplementation (docosahexaenoic acid 71.9 ± 13.9 mg/kg b.w./day plus eicosapentaenoic acid 115.5 ± 22.4 mg/kg b.w./day) for 12 months
Number of subjects: 66
Study 24526821 — intervention group
Group type: COMPARATOR
Intervention: Untreated population (Control)
Number of subjects: 66
Study 20716324 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone diffractive multifocal IOL (Tecnis ZM900)
Number of subjects: 21
Study 20716324 — intervention group
Group type: COMPARATOR
Intervention: Acrylic diffractive multifocal IOL (Tecnis ZMA00)
Number of subjects: 21
Study 21029001 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelnidipine 8‐16 mg/day
Number of subjects: 220
Study 21029001 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine 2.5‐5 mg/day
Number of subjects: 220
Study 16985182 — intervention group
Group type: COMPARATOR
Intervention: Regimen A (doxorubicin, vincristine, cyclophosphamide, dactinomycin)
Number of subjects: 578
Study 16985182 — intervention group
Group type: COMPARATOR
Intervention: Regimen B (doxorubicin, vincristine, cyclophosphamide, dactinomycin alternating with etoposide and ifosfamide)
Number of subjects: 578
Study 16985182 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen C (high-intensity therapy with higher doses of doxorubicin, cyclophosphamide, and ifosfamide)
Number of subjects: 578
Study 16985182 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing exposure to ifosfamide (90 to 140 g/m2), cyclophosphamide (9.6 to 17.6 g/m2), and doxorubicin (375 to 450 mg/m2)
Number of subjects: 578
Study 16358235 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime-heparin lock solution
Number of subjects: 208
Study 16358235 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 208
Study 12028163 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatric Evaluation and Management Unit (GEMU) treatment
Number of subjects: 254
Study 12028163 — intervention group
Group type: COMPARATOR
Intervention: Control group (traditional treatment in Department of Internal Medicine)
Number of subjects: 254
Study 11176980 — intervention group
Group type: EXPERIMENTAL
Intervention: Verteporfin
Number of subjects: 609
Study 11176980 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 609
Study 11176980 — intervention group
Group type: EXPERIMENTAL
Intervention: Verteporfin (predominantly classic lesions)
Number of subjects: 609
Study 11176980 — intervention group
Group type: COMPARATOR
Intervention: Placebo (predominantly classic lesions)
Number of subjects: 609
Study 11176980 — intervention group
Group type: EXPERIMENTAL
Intervention: Verteporfin (minimally classic lesions)
Number of subjects: 609
Study 11176980 — intervention group
Group type: COMPARATOR
Intervention: Placebo (minimally classic lesions)
Number of subjects: 609
Study 9145823 — intervention group
Group type: EXPERIMENTAL
Intervention: Fleroxacin 400 mg od for 10 days
Number of subjects: 411
Study 9145823 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline 100 mg bd for 10 days
Number of subjects: 411
Study 9145823 — intervention group
Group type: EXPERIMENTAL
Intervention: Fleroxacin
Number of subjects: 411
Study 9145823 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline
Number of subjects: 411
Study 7967272 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous warm blood cardioplegia (CWBC)
Number of subjects: 24
Study 7967272 — intervention group
Group type: COMPARATOR
Intervention: Intermittent cold GIK cardioplegia (ICGC)
Number of subjects: 24
Study 3480076 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftizoxime
Number of subjects: 50
Study 3480076 — intervention group
Group type: COMPARATOR
Intervention: Cefoxitin/Doxycycline
Number of subjects: 50
Study 29204924 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleomycin microneedle patch
Number of subjects: 42
Study 29204924 — intervention group
Group type: COMPARATOR
Intervention: Cryotherapy
Number of subjects: 42
Study 26944837 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-acting β-agonists
Number of subjects: 1176
Study 26944837 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily maintenance medications
Number of subjects: 1176
Study 26944837 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma action plan
Number of subjects: 1176
Study 26944837 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of control
Number of subjects: 1176
Study 26944837 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaler technique education
Number of subjects: 1176
Study 26944837 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication adherence assessment
Number of subjects: 1176
Study 26944837 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergy evaluation
Number of subjects: 1176
Study 26944837 — intervention group
Group type: EXPERIMENTAL
Intervention: No asthma-related visit in the year before enrollment
Number of subjects: 1176
Study 25509976 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracervical anesthesia (10 ml %2 prilocaine)
Number of subjects: 200
Study 25509976 — intervention group
Group type: COMPARATOR
Intervention: No anesthesia
Number of subjects: 200
Study 23589143 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid nutrient meal (LNM; Ensure Plus(®))
Number of subjects: 20
Study 23589143 — intervention group
Group type: COMPARATOR
Intervention: Solid meal (egg‐white sandwich, EWS)
Number of subjects: 20
Study 23589143 — intervention group
Group type: EXPERIMENTAL
Intervention: Wireless motility capsule (WMC; SmartPill(®))
Number of subjects: 20
Study 20803165 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral prescription to read the self-help book, Feeling Good
Number of subjects: 38
Study 20803165 — intervention group
Group type: COMPARATOR
Intervention: Usual care treatment for depression (often involves medication)
Number of subjects: 38
Study 19469296 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine 0.5 mg/ml + ketamine 0.5 mg/ml (MK-group)
Number of subjects: 138
Study 19469296 — intervention group
Group type: COMPARATOR
Intervention: Morphine 0.5 mg/ml + placebo (M-group)
Number of subjects: 138
Study 16243243 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.25% or 2.5% ethanolamine oleate
Number of subjects: 27
Study 16243243 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 27
Study 12522747 — intervention group
Group type: EXPERIMENTAL
Intervention: Linezolid (600 mg intravenously or orally every 12 h)
Number of subjects: 796
Study 10659081 — intervention group
Group type: EXPERIMENTAL
Intervention: Full attention condition
Number of subjects: 0
Study 10659081 — intervention group
Group type: COMPARATOR
Intervention: Divided attention condition
Number of subjects: 0
Study 10659081 — intervention group
Group type: EXPERIMENTAL
Intervention: Completion task with memory strategies
Number of subjects: 0
Study 8681490 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine gum (2 mg nicotine per piece, at least six pieces per day)
Number of subjects: 29
Study 8681490 — intervention group
Group type: COMPARATOR
Intervention: Cigarette smoking
Number of subjects: 29
Study 1947721 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin infusion (2 mU kg‐1 min‐1) with volume expansion (2 L isotonic sodium chloride) for 2 hours
Number of subjects: 6
Study 1947721 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin infusion without volume expansion
Number of subjects: 6
Study 1947721 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined hyperinsulinaemia and volume expansion
Number of subjects: 6
Study 1947721 — intervention group
Group type: COMPARATOR
Intervention: Control (Day B: no insulin and glucose infusion)
Number of subjects: 6
Study 31136288 — intervention group
Group type: EXPERIMENTAL
Intervention: Early intensive blood pressure lowering
Number of subjects: 2598
Study 31136288 — intervention group
Group type: COMPARATOR
Intervention: Guideline-recommended blood pressure lowering
Number of subjects: 2598
Study 29023178 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquamin F™ (derived from Lithothamnion sp.)
Number of subjects: 12
Study 29023178 — intervention group
Group type: COMPARATOR
Intervention: Calcium carbonate
Number of subjects: 12
Study 29023178 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 26466128 — intervention group
Group type: EXPERIMENTAL
Intervention: Custom-made (CM) mouthguard
Number of subjects: 10
Study 26466128 — intervention group
Group type: COMPARATOR
Intervention: Standard (BB) mouthguard
Number of subjects: 10
Study 26466128 — intervention group
Group type: COMPARATOR
Intervention: No mouthguard (CON)
Number of subjects: 10
Study 27128612 — intervention group
Group type: EXPERIMENTAL
Intervention: MF 800 µg + F 20 µg coadministered (MF + F)
Number of subjects: 0
Study 27128612 — intervention group
Group type: EXPERIMENTAL
Intervention: MF 800 µg/F 20 µg (MF/F)
Number of subjects: 0
Study 27128612 — intervention group
Group type: COMPARATOR
Intervention: MF 800 µg
Number of subjects: 0
Study 27128612 — intervention group
Group type: COMPARATOR
Intervention: F 20 µg
Number of subjects: 0
Study 22139393 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal orthosis (Thämert Osteo-med)
Number of subjects: 69
Study 22139393 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 69
Study 20702114 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan (4 mg/day)
Number of subjects: 40
Study 20702114 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril (4 mg/day)
Number of subjects: 40
Study 20702114 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (topical nitrate only when SBP ≥220 mm Hg or DBP ≥120 mm Hg)
Number of subjects: 40
Study 17211270 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalteparin (5000 U) given subcutaneously once daily for 6 weeks postoperatively
Number of subjects: 105
Study 17211270 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study 15882789 — intervention group
Group type: EXPERIMENTAL
Intervention: Unidirectional task
Number of subjects: 10
Study 15882789 — intervention group
Group type: EXPERIMENTAL
Intervention: Bidirectional task
Number of subjects: 10
Study 12210616 — intervention group
Group type: EXPERIMENTAL
Intervention: Network meta-analysis techniques for treatment comparisons
Number of subjects: 0
Study 9589308 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized controlled trials (RCTs)
Number of subjects: 0
Study 7892492 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadolinium-enhanced magnetization transfer (MT) MR imaging
Number of subjects: 86
Study 7892492 — intervention group
Group type: COMPARATOR
Intervention: Conventional T1-weighted MR imaging
Number of subjects: 86
Study 7892492 — intervention group
Group type: COMPARATOR
Intervention: Non-enhanced T1-weighted MT images
Number of subjects: 86
Study 2796369 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical vancomycin applied to cut sternal edges (group V)
Number of subjects: 416
Study 2796369 — intervention group
Group type: COMPARATOR
Intervention: Control group (no topical vancomycin, only hemostatic paste)
Number of subjects: 416
Study 273143 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal methotrexate
Number of subjects: 32
Study 273143 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal cytosine arabinoside
Number of subjects: 32
Study 273143 — intervention group
Group type: COMPARATOR
Intervention: Control group (no CNS prophylaxis)
Number of subjects: 32
Study 273143 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall (both intrathecal chemotherapy groups)
Number of subjects: 32
Study 31392826 — intervention group
Group type: EXPERIMENTAL
Intervention: Five long noncoding RNAs (AATK‐AS1, C10orf91, LINC00162, LINC00200, and LINC00501) used to predict overall survival (OS) based on gene expression and regression coefficients.
Number of subjects: 313
Study 31392826 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup analysis of the five lncRNAs in early-stage liver cancer.
Number of subjects: 313
Study 31392826 — intervention group
Group type: EXPERIMENTAL
Intervention: Association of the five lncRNAs with immune cell infiltration.
Number of subjects: 313
Study 31392826 — intervention group
Group type: EXPERIMENTAL
Intervention: KEGG pathway enrichment analysis of coexpressed modules.
Number of subjects: 313
Study 27489178 — intervention group
Group type: EXPERIMENTAL
Intervention: Migraine-specific medication (MSM)
Number of subjects: 337
Study 27489178 — intervention group
Group type: EXPERIMENTAL
Intervention: Over-the-counter analgesic (OTC)
Number of subjects: 337
Study 27489178 — intervention group
Group type: EXPERIMENTAL
Intervention: Opiate/barbiturate
Number of subjects: 337
Study 25195547 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 fish oil 3000 mg/day
Number of subjects: 41
Study 25195547 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 23972905 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet group
Number of subjects: 243
Study 23972905 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group
Number of subjects: 243
Study 23972905 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 243
Study 21892200 — intervention group
Group type: EXPERIMENTAL
Intervention: Antofloxacin (400 mg on day 1 and 200 mg on days 2 to 5)
Number of subjects: 12
Study 21892200 — intervention group
Group type: COMPARATOR
Intervention: Theophylline (100 mg twice a day and morning dose 200 mg on days 1 and 5)
Number of subjects: 12
Study 21892200 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline plus antofloxacin
Number of subjects: 12
Study 19515236 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral metronidazole
Number of subjects: 53
Study 19515236 — intervention group
Group type: COMPARATOR
Intervention: Vaginal metronidazole
Number of subjects: 53
Study 19515236 — intervention group
Group type: EXPERIMENTAL
Intervention: Both oral and vaginal metronidazole
Number of subjects: 53
Study 18028134 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved bone marrow culture cells
Number of subjects: 0
Study 18028134 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous bone marrow aspirate and cultured bone marrow cells
Number of subjects: 0
Study 15040827 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 60 or 120 mg/day for 3 years
Number of subjects: 7705
Study 11338965 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-training intervention (Preparing for the Drug Free Years)
Number of subjects: 209
Study 11338965 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control condition
Number of subjects: 209
Study 9215438 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational injury interventions
Number of subjects: 0
Study 9215438 — intervention group
Group type: EXPERIMENTAL
Intervention: Quasi-experimental studies
Number of subjects: 0
Study 9215438 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative studies
Number of subjects: 0
Study 9215438 — intervention group
Group type: COMPARATOR
Intervention: Simple quasi-experimental designs
Number of subjects: 0
Study 9215438 — intervention group
Group type: COMPARATOR
Intervention: More elaborate quasi-experimental designs
Number of subjects: 0
Study 9215438 — intervention group
Group type: COMPARATOR
Intervention: Randomized controlled trials
Number of subjects: 0
Study 8432448 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecystokinin octapeptide 5 ng/kg
Number of subjects: 14
Study 8432448 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecystokinin octapeptide 10 ng/kg
Number of subjects: 14
Study 8432448 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecystokinin octapeptide 20 ng/kg
Number of subjects: 14
Study 3307520 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 mg midazolam
Number of subjects: 120
Study 3307520 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg midazolam
Number of subjects: 120
Study 3307520 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg diazepam
Number of subjects: 120
Study 3307520 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 30198774 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing
Number of subjects: 130
Study 30198774 — intervention group
Group type: COMPARATOR
Intervention: Conventional education
Number of subjects: 130
Study 31278067 — intervention group
Group type: EXPERIMENTAL
Intervention: Epigallocatechin gallate (400 mg capsule, orally once daily for 4 weeks, then twice daily for 4 weeks, then three times daily for 40 weeks)
Number of subjects: 92
Study 31278067 — intervention group
Group type: COMPARATOR
Intervention: Placebo (mannitol, same dosing schedule as epigallocatechin gallate)
Number of subjects: 92
Study 31278067 — intervention group
Group type: EXPERIMENTAL
Intervention: Epigallocatechin gallate
Number of subjects: 92
Study 31278067 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study 28544992 — intervention group
Group type: EXPERIMENTAL
Intervention: USL261 2.5mg
Number of subjects: 30
Study 28544992 — intervention group
Group type: EXPERIMENTAL
Intervention: USL261 5.0mg
Number of subjects: 30
Study 28544992 — intervention group
Group type: EXPERIMENTAL
Intervention: USL261 (both doses)
Number of subjects: 30
Study 28544992 — intervention group
Group type: EXPERIMENTAL
Intervention: USL261
Number of subjects: 30
Study 25499545 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A (50,000 IU)
Number of subjects: 22955
Study 25499545 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22955
Study 23613014 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 10 mg
Number of subjects: 2
Study 23613014 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2